Literature DB >> 6749591

Combination antitumor therapy with lentinan and bacterial lipopolysaccharide against murine tumors.

S Abe, O Yoshioka, Y Masuko, J Tsubouchi, M Kohno, H Nakajima, M Yamazaki, D Mizono.   

Abstract

The antitumor effects of lentinan and bacterial lipopolysaccharide (LPS) were studied. Combined treatment with lentinan and LPS was very effective against Ehrlich carcinoma in ddY mice, and the syngeneic mammary carcinoma MM46 in C3H/He mice. Studies on the effective doses and times of administration showed that a single injection of lentinan plus LPS 12 days after subcutaneous inoculation of these tumors caused complete regression in 60 approximately 90% of the animals; complete regression of MM46 carcinoma was seen in 83% of the animals.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6749591

Source DB:  PubMed          Journal:  Gan        ISSN: 0016-450X


  4 in total

1.  Sonic hedgehog antagonists induce cell death in acute myeloid leukemia cells with the presence of lipopolysaccharides, tumor necrosis factor-α, or interferons.

Authors:  Frank Leigh Lu; Ching-Chia Yu; Huei-Hsuan Chiu; Hsingjin Eugene Liu; Shao-Yin Chen; Shufan Lin; Ting-Yi Goh; Hsin-Chih Hsu; Chih-Han Chien; Han-Chung Wu; Ming-Shan Chen; Scott C Schuyler; Wu-Shiun Hsieh; Mei-Hwan Wu; Jean Lu
Journal:  Invest New Drugs       Date:  2012-12-13       Impact factor: 3.850

2.  Therapeutic ratio of mono or combination bacterial lipopolysaccharide therapy in methylnitrosourea-induced rat mammary carcinoma.

Authors:  M R Berger; E Petru; D Schmähl
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

3.  Activation of tumor-infiltrating macrophages by a synthetic lipid A analog (ONO-4007) and its implication in antitumor effects.

Authors:  D Yang; M Satoh; H Ueda; S Tsukagoshi; M Yamazaki
Journal:  Cancer Immunol Immunother       Date:  1994-05       Impact factor: 6.968

4.  Anti-tumour activity of low-toxicity lipopolysaccharide of Bordetella pertussis.

Authors:  M Ohnishi; S Kimura; M Yamazaki; H Oshima; D I Mizuno; S Abe; H Yamaguchi
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.